insights_auto
Zašto je SOBI pao 2,81%?
Istražite detaljnijechevron_right
SOBI:STO
Swedish Orphan Biovitrum
421,40 SEK
arrow_downward
−2,81%(−12,20) 1D
13. lis, 16:09:04 GMT+2 · SEK
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za SOBI...
Otvori
433,60 SEK
Najviša
437,40 SEK
Najniža
421,20 SEK
Trž. kap.
150,71 mlr.
Prosj. kol.
269,95 tis.
Količina
70,96 tis.
P/E omjer
112,55
52-tjed. najviša
487,00 SEK
52-tjed. najniža
293,60 SEK
EPS
3,74 SEK
Dionice u optjecaju
357,64 mil.
Broj djelatnika
2 tis.
Otvori
433,60 SEK
Najviša
437,40 SEK
Najniža
421,20 SEK
Trž. kap.
150,71 mlr.
Prosj. kol.
269,95 tis.
Količina
70,96 tis.
P/E omjer
112,55
52-tjed. najviša
487,00 SEK
52-tjed. najniža
293,60 SEK
EPS
3,74 SEK
Dionice u optjecaju
357,64 mil.
Broj djelatnika
2 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Yahoo Finance
·
prije 1 dan
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline
Profil
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
Swedish Orphan Biovitrum – informacije
Glavni izvršni direktorGuido Oelkers
Zaposlenici2,12 tis.
Osnovano1939
Sjedište-
Sektor-
Web-lokacijasobi.com